vs
ARTIVION, INC.（AORT）与泰利福（TFX）财务数据对比。点击上方公司名可切换其他公司
泰利福净利率更高（177.8% vs 2.1%，领先175.7%）。ARTIVION, INC.同比增速更快（19.2% vs -150.5%）。ARTIVION, INC.自由现金流更多（$-7.9M vs $-92.9M）。过去两年泰利福的营收复合增速更高（NaN% vs NaN%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
泰利福（Teleflex）总部位于美国宾夕法尼亚州韦恩，是专业医疗设备供应商，产品广泛应用于重症监护、外科手术等各类诊疗场景。公司年营收达24亿美元，在全球40个国家开展业务，员工总数超15000人。经过数年的收并购与业务剥离，公司于2011年完成业务调整，全面聚焦医疗设备制造领域。
AORT vs TFX — 直观对比
营收规模更大
AORT
是对方的-0.3倍
$-401.9M
营收增速更快
AORT
高出169.7%
-150.5%
净利率更高
TFX
高出175.7%
2.1%
自由现金流更多
AORT
多$85.0M
$-92.9M
两年增速更快
TFX
近两年复合增速
9.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $-401.9M |
| 净利润 | $2.4M | $-714.3M |
| 毛利率 | 63.1% | — |
| 营业利润率 | 9.2% | — |
| 净利率 | 2.1% | 177.8% |
| 营收同比 | 19.2% | -150.5% |
| 净利润同比 | 114.7% | -422.7% |
| 每股收益（稀释后） | $0.06 | $-15.85 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTTFX
| Q4 25 | $116.0M | $-401.9M | ||
| Q3 25 | $113.4M | $913.0M | ||
| Q2 25 | $113.0M | $780.9M | ||
| Q1 25 | $99.0M | $700.7M | ||
| Q4 24 | $97.3M | $795.4M | ||
| Q3 24 | $95.8M | $764.4M | ||
| Q2 24 | $98.0M | $749.7M | ||
| Q1 24 | $97.4M | $737.8M |
净利润AORTTFX
| Q4 25 | $2.4M | $-714.3M | ||
| Q3 25 | $6.5M | $-408.9M | ||
| Q2 25 | $1.3M | $122.6M | ||
| Q1 25 | $-505.0K | $95.0M | ||
| Q4 24 | $-16.5M | $-136.7M | ||
| Q3 24 | $-2.3M | $111.0M | ||
| Q2 24 | $-2.1M | $80.0M | ||
| Q1 24 | $7.5M | $15.3M |
毛利率AORTTFX
| Q4 25 | 63.1% | — | ||
| Q3 25 | 65.6% | 49.5% | ||
| Q2 25 | 64.7% | 55.2% | ||
| Q1 25 | 64.2% | 55.6% | ||
| Q4 24 | 63.2% | 55.3% | ||
| Q3 24 | 63.7% | 56.3% | ||
| Q2 24 | 64.6% | 55.6% | ||
| Q1 24 | 64.6% | 56.4% |
营业利润率AORTTFX
| Q4 25 | 9.2% | — | ||
| Q3 25 | 11.1% | -44.8% | ||
| Q2 25 | 7.4% | 19.9% | ||
| Q1 25 | 2.2% | 17.9% | ||
| Q4 24 | 2.7% | -13.9% | ||
| Q3 24 | 4.6% | 19.5% | ||
| Q2 24 | 6.6% | 15.6% | ||
| Q1 24 | 26.0% | -0.6% |
净利率AORTTFX
| Q4 25 | 2.1% | 177.8% | ||
| Q3 25 | 5.7% | -44.8% | ||
| Q2 25 | 1.2% | 15.7% | ||
| Q1 25 | -0.5% | 13.6% | ||
| Q4 24 | -16.9% | -17.2% | ||
| Q3 24 | -2.4% | 14.5% | ||
| Q2 24 | -2.2% | 10.7% | ||
| Q1 24 | 7.7% | 2.1% |
每股收益（稀释后）AORTTFX
| Q4 25 | $0.06 | $-15.85 | ||
| Q3 25 | $0.13 | $-9.24 | ||
| Q2 25 | $0.03 | $2.77 | ||
| Q1 25 | $-0.01 | $2.07 | ||
| Q4 24 | $-0.40 | $-2.89 | ||
| Q3 24 | $-0.05 | $2.36 | ||
| Q2 24 | $-0.05 | $1.69 | ||
| Q1 24 | $0.18 | $0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $378.6M |
| 总债务越低越好 | $215.1M | $2.6B |
| 股东权益账面价值 | $448.2M | $3.1B |
| 总资产 | $884.8M | $6.9B |
| 负债/权益比越低杠杆越低 | 0.48× | 0.85× |
8季度趋势，按日历期对齐
现金及短期投资AORTTFX
| Q4 25 | $64.9M | $378.6M | ||
| Q3 25 | $73.4M | $354.0M | ||
| Q2 25 | $53.5M | $253.7M | ||
| Q1 25 | $37.7M | $284.1M | ||
| Q4 24 | $53.5M | $290.2M | ||
| Q3 24 | $56.2M | $243.2M | ||
| Q2 24 | $55.0M | $238.6M | ||
| Q1 24 | $51.1M | $237.4M |
总债务AORTTFX
| Q4 25 | $215.1M | $2.6B | ||
| Q3 25 | $214.9M | $2.7B | ||
| Q2 25 | $215.6M | $1.9B | ||
| Q1 25 | $314.7M | $1.9B | ||
| Q4 24 | $314.3M | $1.7B | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
股东权益AORTTFX
| Q4 25 | $448.2M | $3.1B | ||
| Q3 25 | $438.7M | $3.8B | ||
| Q2 25 | $419.9M | $4.2B | ||
| Q1 25 | $294.3M | $4.1B | ||
| Q4 24 | $276.2M | $4.3B | ||
| Q3 24 | $304.7M | $4.5B | ||
| Q2 24 | $295.1M | $4.6B | ||
| Q1 24 | $295.0M | $4.5B |
总资产AORTTFX
| Q4 25 | $884.8M | $6.9B | ||
| Q3 25 | $857.7M | $7.9B | ||
| Q2 25 | $838.4M | $7.4B | ||
| Q1 25 | $791.2M | $7.2B | ||
| Q4 24 | $789.1M | $7.1B | ||
| Q3 24 | $803.1M | $7.5B | ||
| Q2 24 | $789.5M | $7.4B | ||
| Q1 24 | $784.0M | $7.5B |
负债/权益比AORTTFX
| Q4 25 | 0.48× | 0.85× | ||
| Q3 25 | 0.49× | 0.70× | ||
| Q2 25 | 0.51× | 0.45× | ||
| Q1 25 | 1.07× | 0.47× | ||
| Q4 24 | 1.14× | 0.39× | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $-92.3M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | $-92.9M |
| 自由现金流率自由现金流/营收 | -6.9% | 23.1% |
| 资本支出强度资本支出/营收 | 23.7% | -0.2% |
| 现金转化率经营现金流/净利润 | 8.06× | — |
| 过去12个月自由现金流最近4个季度 | $839.0K | $1.4M |
8季度趋势，按日历期对齐
经营现金流AORTTFX
| Q4 25 | $19.6M | $-92.3M | ||
| Q3 25 | $22.3M | $107.8M | ||
| Q2 25 | $15.0M | $7.8M | ||
| Q1 25 | $-17.0M | $73.3M | ||
| Q4 24 | $10.1M | $202.6M | ||
| Q3 24 | $11.5M | $231.1M | ||
| Q2 24 | $6.1M | $91.7M | ||
| Q1 24 | $-5.5M | $112.8M |
自由现金流AORTTFX
| Q4 25 | $-7.9M | $-92.9M | ||
| Q3 25 | $17.7M | $77.8M | ||
| Q2 25 | $11.7M | $-26.8M | ||
| Q1 25 | $-20.6M | $43.3M | ||
| Q4 24 | $8.7M | $170.6M | ||
| Q3 24 | $7.8M | $209.9M | ||
| Q2 24 | $3.6M | $56.9M | ||
| Q1 24 | $-9.1M | $74.4M |
自由现金流率AORTTFX
| Q4 25 | -6.9% | 23.1% | ||
| Q3 25 | 15.6% | 8.5% | ||
| Q2 25 | 10.4% | -3.4% | ||
| Q1 25 | -20.8% | 6.2% | ||
| Q4 24 | 9.0% | 21.4% | ||
| Q3 24 | 8.2% | 27.5% | ||
| Q2 24 | 3.7% | 7.6% | ||
| Q1 24 | -9.3% | 10.1% |
资本支出强度AORTTFX
| Q4 25 | 23.7% | -0.2% | ||
| Q3 25 | 4.1% | 3.3% | ||
| Q2 25 | 2.9% | 4.4% | ||
| Q1 25 | 3.7% | 4.3% | ||
| Q4 24 | 1.5% | 4.0% | ||
| Q3 24 | 3.8% | 2.8% | ||
| Q2 24 | 2.6% | 4.6% | ||
| Q1 24 | 3.7% | 5.2% |
现金转化率AORTTFX
| Q4 25 | 8.06× | — | ||
| Q3 25 | 3.42× | — | ||
| Q2 25 | 11.16× | 0.06× | ||
| Q1 25 | — | 0.77× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.08× | ||
| Q2 24 | — | 1.15× | ||
| Q1 24 | -0.73× | 7.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
TFX
暂无分部数据
